Supplementary Data from <i>N</i><sup>6</sup>-methyladenosine Modification of FZR1 mRNA Promotes Gemcitabine Resistance in Pancreatic Cancer

Supplementary Data from <i>N</i><sup>6</sup>-methyladenosine Modification of FZR1 mRNA Promotes Gemcitabine Resistance in Pancreatic Cancer

<p>Proteins identified in RNA pulldown and mass spectrometry analysis with FZR1[m6A] or FZR1[A].</p>

Furkejuvvon:

Bibliográfalaš dieđut
Váldodahkki:	Jiachun Su (16990970) (author)
Eará dahkkit:	Rui Li (16990973) (author), Ziming Chen (16990976) (author), Shaoqiu Liu (16990979) (author), Hongzhe Zhao (16990982) (author), Shuang Deng (16990985) (author), Lingxing Zeng (16990988) (author), Zilan Xu (16990991) (author), Sihan Zhao (16990994) (author), Yifan Zhou (16990997) (author), Mei Li (16991000) (author), Xiaowei He (16991003) (author), Ji Liu (16991006) (author), Chunling Xue (16991009) (author), Ruihong Bai (16991012) (author), Lisha Zhuang (16991015) (author), Quanbo Zhou (16991018) (author), Shaoping Zhang (16991021) (author), Rufu Chen (16991024) (author), Xudong Huang (16991027) (author), Dongxin Lin (16991030) (author), Jian Zheng (11732682) (author), Jialiang Zhang (16991033) (author)
Almmustuhtton:	2025
Fáttát:	Cancer Cancer Risk Factors Molecular and Cellular Biology Therapeutic Research and Development Chemotherapy Drug Resistance Regulation of gene expression in drug resistance Epigenetics Gastrointestinal Cancers Pancreatic cancer
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!

Geahča maid

Figure S1 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
Dahkki: Dahihm Kim (16546203)
Almmustuhtton: (2025)

Figure S2 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
Dahkki: Dahihm Kim (16546203)
Almmustuhtton: (2025)

Figure S3 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
Dahkki: Dahihm Kim (16546203)
Almmustuhtton: (2025)

Figure S4 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
Dahkki: Dahihm Kim (16546203)
Almmustuhtton: (2025)

Figure S5 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
Dahkki: Dahihm Kim (16546203)
Almmustuhtton: (2025)

Table S1 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
Dahkki: Dahihm Kim (16546203)
Almmustuhtton: (2025)

Table S3 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
Dahkki: Dahihm Kim (16546203)
Almmustuhtton: (2025)

Supplementary Figure S1 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
Dahkki: Chong Kin Liam (15331321)
Almmustuhtton: (2025)

Supplementary Figure S2 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
Dahkki: Chong Kin Liam (15331321)
Almmustuhtton: (2025)

Supplementary Figure S3 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
Dahkki: Chong Kin Liam (15331321)
Almmustuhtton: (2025)

Supplementary Figure S4 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
Dahkki: Chong Kin Liam (15331321)
Almmustuhtton: (2025)

Supplementary Data 1 from Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration
Dahkki: Gregory L. Beatty (15087193)
Almmustuhtton: (2025)

Supplementary Data 2 from Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration
Dahkki: Gregory L. Beatty (15087193)
Almmustuhtton: (2025)

Supplementary Table from CircIPO7 Promotes Nasopharyngeal Carcinoma Metastasis and Cisplatin Chemoresistance by Facilitating YBX1 Nuclear Localization
Dahkki: Xiaohong Hong (22681698)
Almmustuhtton: (2025)

Supplementary Table S1 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
Dahkki: Sanna Pikkusaari (15055802)
Almmustuhtton: (2025)

Supplementary Table S2 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
Dahkki: Sanna Pikkusaari (15055802)
Almmustuhtton: (2025)

Supplementary Table S1 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
Dahkki: Yufang Bao (15386826)
Almmustuhtton: (2025)

Supplementary Table S2 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
Dahkki: Yufang Bao (15386826)
Almmustuhtton: (2025)

Supplementary Table S3 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
Dahkki: Yufang Bao (15386826)
Almmustuhtton: (2025)

Supplementary Table S4 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
Dahkki: Yufang Bao (15386826)
Almmustuhtton: (2025)

Supplementary Table S5 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
Dahkki: Yufang Bao (15386826)
Almmustuhtton: (2025)

Supplementary Table 1 from <i>N<sup>6</sup></i>-Methyladenosine Promotes Translation of VEGFA to Accelerate Angiogenesis in Lung Cancer
Dahkki: Haisheng Zhang (16436982)
Almmustuhtton: (2025)

Source Data from Ablation of p57<sup>+</sup> Quiescent Cancer Stem Cells Suppresses Recurrence after Chemotherapy of Intestinal Tumors
Dahkki: Takeru Oka (15386810)
Almmustuhtton: (2025)

Supplementary Table S1 from Ablation of p57<sup>+</sup> Quiescent Cancer Stem Cells Suppresses Recurrence after Chemotherapy of Intestinal Tumors
Dahkki: Takeru Oka (15386810)
Almmustuhtton: (2025)

Supplementary Figure 1 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Dahkki: Seung Yeon Oh (15051017)
Almmustuhtton: (2025)

Supplementary Figure 10 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Dahkki: Seung Yeon Oh (15051017)
Almmustuhtton: (2025)

Supplementary Figure 2 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Dahkki: Seung Yeon Oh (15051017)
Almmustuhtton: (2025)

Supplementary Figure 3 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Dahkki: Seung Yeon Oh (15051017)
Almmustuhtton: (2025)

Supplementary Figure 4 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Dahkki: Seung Yeon Oh (15051017)
Almmustuhtton: (2025)

Supplementary Figure 5 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Dahkki: Seung Yeon Oh (15051017)
Almmustuhtton: (2025)

Supplementary Figure 6 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Dahkki: Seung Yeon Oh (15051017)
Almmustuhtton: (2025)

Supplementary Figure 7 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Dahkki: Seung Yeon Oh (15051017)
Almmustuhtton: (2025)

Supplementary Figure 8 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Dahkki: Seung Yeon Oh (15051017)
Almmustuhtton: (2025)

Supplementary Figure 9 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Dahkki: Seung Yeon Oh (15051017)
Almmustuhtton: (2025)

Supplementary Table 1 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Dahkki: Seung Yeon Oh (15051017)
Almmustuhtton: (2025)

Supplementary Table 2 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC
Dahkki: Seung Yeon Oh (15051017)
Almmustuhtton: (2025)

Supplementary Table S1 from Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer
Dahkki: Nicole A. Traphagen (16677391)
Almmustuhtton: (2025)

Supplementary Table S2 from Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer
Dahkki: Nicole A. Traphagen (16677391)
Almmustuhtton: (2025)

Data file S1 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
Dahkki: Alex C.H. Liu (14961921)
Almmustuhtton: (2025)

Data file S2 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
Dahkki: Alex C.H. Liu (14961921)
Almmustuhtton: (2025)

Cannot write session to /tmp/vufind_sessions/sess_nicorh8argrl6pmiifebrtc131